CD4/CD8 T-Cell Ratio

A healthy adult carries roughly twice as many CD4 helper T cells as CD8 cytotoxic T cells. With age the CD8 compartment expands into large oligoclonal populations, often driven by chronic cytomegalovirus infection, while the naive CD4 supply shrinks as the thymus involutes. When the ratio drops below 1.0 it is called inversion, and it is the single most cited component of the immune risk profile.

Jan Olsson and Anders Wikby documented this in the Swedish OCTO immune study, following very old individuals from 1989 to a fourth assessment 8 years later. Inversion of the CD4/CD8 ratio occurred in 32% of the original sample over the study period [1]. The combination of high CD8 percentage, low CD4 percentage and poor T-cell proliferation was associated with higher 2-year mortality, and that combination was closely tied to the inverted ratio [1]. In inverted individuals, CD4 counts fell while CD8 counts rose sharply, with the expansion concentrated in CD8+CD28- and CD57+ subsets, the markers of terminally differentiated cells. Cytomegalovirus serostatus was associated with the whole pattern [1].

Inversion is not rare in younger old age. Jan Strindhall, Jan Ernerudh and Anders Wikby drew a population-based sample of 66-year-olds in Jonkoping, Sweden. From 1,310 eligible residents, 655 were invited and 424 enrolled, 227 women and 197 men. A second-stage sample of 151 people was split into 50 with a ratio below 1 and 101 with a ratio above 1.2 for deeper profiling of naive and TEMRA subsets, B cells and CMV serology [2].

The mortality link does not travel everywhere. Graham Pawelec compared the Swedish OCTO/NONA findings in 85-year-olds against Dutch and Belgian cohorts and concluded the immune parameters associated with mortality are context-dependent [3]. Rachel Thomas and Dong-Ming Su supply the mechanism: thymic involution, with 80 to 95% of peripheral regulatory T cells normally generated in the thymus [4].

How it is measured: flow cytometry on fresh whole blood, usually EDTA-anticoagulated and analysed within 24 hours, as in the HEXA protocol [2]. It is a dimensionless ratio, so no assay calibration problem arises. It is a standard part of any lymphocyte subset panel and is inexpensive.

How to move it: nothing reliably. No supplement has randomised evidence of reversing inversion. The nearest interventional data target the same axis from above: Joan Mannick's phase 2a trial in 264 elderly subjects used low-dose mTOR inhibition for 6 weeks and cut reported infections over the following year, P = 0.001, with reduced PD-1 expression on CD4 and CD8 cells in the earlier RAD001 study [5][6].